Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...

Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...

Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

DexCom Inc (DXCM) reports strong international growth and expanding customer base, while facing margin pressures and US ...

At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines have been placed on mute to prevent any background noise. After the ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...